Study of AZD3632 for advanced blood cancers with certain gene changes
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing a new drug, AZD3632, either alone or with other cancer treatments, for people with advanced blood cancers that have specific genetic changes (like KMT2Ar, NPM1m, or others that cause HOX over-expression). The goal is to see if it can help when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced blood cancer, such as acute leukemia or MDS, that has come back or not responded to standard treatments.
- Your cancer has a specific gene change (like KMT2Ar or NPM1m) that makes it more likely to respond to this drug.
- Your organs (like kidneys and liver) are working well enough.
- You are able to use effective contraception if needed.
- You have not had certain other cancer treatments or radiation recently (varies by part of the study).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new medicine called AMX-883 for people with a type of blood cancer called acute myeloid leukemia (AML) or a high-risk blood disorder called myelodysplastic syndrome (MDS) that has come back or not responded to other treatments. The study hopes to see if the drug is safe and works, either alone or combined with another drug.
This study tests an experimental drug called AZD3470 for people with certain types of blood cancer (lymphoma) that have come back or not responded to standard treatments. The drug will be given alone or with other cancer medicines to see if it is safe and effective.
This study tests an experimental drug called S241656, either alone or with another medication, for people with certain blood cancers (AML, MDS/AML, or CMML) that haven't responded to standard treatments. The goal is to see if the drug is safe and effective in shrinking or controlling the cancer.
This study tests a new medicine called AZD4512, given alone or with other cancer drugs, for people whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has come back or not improved after treatment. The goal is to see if it can help control the disease.
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
Hear when a new Higher-risk Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.